NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/02/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization507.1 mln
Float143 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
13.38
Transformational upside
Relative Strength
89
/ 100
Strongly outperforming
Debt / Equity
0.26
Very low leverage
ROE
-134
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Cabaletta Bio is a Philadelphia-based clinical-stage company developing specialized cell therapies designed to treat a broad range of autoimmune diseases. Its most advanced treatment, resecabtagene autoleucel, is being tested in clinical trials across more than ten conditions, including lupus, multiple sclerosis, and myasthenia gravis, while two additional therapies target specific forms of the skin disorder pemphigus vulgaris and a muscle-weakening antibody-driven disease. The company works alongside leading research institutions and biotech partners to advance its pipeline, and has operated under its current name since 2018.
